According to a research conducted at UC Davis Cancer Center, patients taking bortezomib plus gemcitabine and carboplatin had a median survival of 11 months. Nine months was the longest median survival in earlier SWOG trials of platinum-based chemotherapy for advanced non-cell lung cancer. The research report was presented at the annual meeting of American Society of Clinical Oncology.
According to the researchers, the survival result is among the best, ever reported. They are now looking forward to another research of bortezomib combined with chemotherapy as treatment for NSCLC in phase III trial. The National Cancer Institute grants funds for this research.
Read